Clinical Trial Update: Intranasal Bevacizumab for HHT-Related Epistaxis [Phase 4]

View source ↗

Summary

Phase 4 trial update on intranasal bevacizumab for hereditary hemorrhagic telangiectasia (HHT) with epistaxis has completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epistaxis
• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Stanford University | Conditions: HHT, Hereditary Hemorrhagic Telangiectasia | Phase 4 | Status: COMPLETED | Results posted: 2021-02-15